139 related articles for article (PubMed ID: 8695876)
61. Selective depletion of CD8-positive T-lymphocytes for allogeneic bone marrow transplantation: engraftment, graft-versus-host disease and graft-versus leukemia.
Champlin R; Giralt S; Przepiorka D; Ho W; Lee K; Gajewski J; Nimer S; Andersson B; Wallerstein R; Ippolito C
Prog Clin Biol Res; 1992; 377():385-94; discussion 395-8. PubMed ID: 1438435
[No Abstract] [Full Text] [Related]
62. [Autologous bone marrow transplantation for CML].
Nagamura F; Nagamura-Inoue T
Nihon Rinsho; 2001 Dec; 59(12):2369-74. PubMed ID: 11766341
[TBL] [Abstract][Full Text] [Related]
63. Autologous blood stem-cell transplantation and recombinant interferon alfa in chronic myeloid leukemia.
Reiffers J; Montastruc M; Cahn JY; Souillet G; Troncy J; Leblond V; Caillot D; Troussard X; Marit G; Fabères C
Semin Hematol; 1993 Jul; 30(3 Suppl 3):51-2. PubMed ID: 8235709
[No Abstract] [Full Text] [Related]
64. Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Skórski T; Szczylik C; Malaguarnera L; Calabretta B
Folia Histochem Cytobiol; 1991; 29(3):85-9. PubMed ID: 1794439
[TBL] [Abstract][Full Text] [Related]
65. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
Chasty R; Whetton A; Lucas G
Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
[TBL] [Abstract][Full Text] [Related]
66. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
Douay L; Hu C; Giarratana MC; Bouchet S; Conlon J; Capizzi RL; Gorin NC
Blood; 1995 Oct; 86(7):2849-55. PubMed ID: 7670119
[TBL] [Abstract][Full Text] [Related]
67. Enhanced elimination of Ph+ chromosome cells in vitro by combined hyperthermia and other drugs (AZT, IFN-alpha, TNF, and quercetin): its application to autologous bone marrow transplantation for CML.
Osman Y; Moriyama Y; Shibata A
Exp Hematol; 1995 May; 23(5):444-52. PubMed ID: 7720816
[TBL] [Abstract][Full Text] [Related]
68. Autografting for chronic myelogenous leukemia.
Bhatia R; Verfaillie CM
Curr Opin Hematol; 1995 Nov; 2(6):436-43. PubMed ID: 9372033
[TBL] [Abstract][Full Text] [Related]
69. Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
Corsetti MT; Lerma E; Dejana A; Cavaliere M; Figari O; Vassallo F; Abate M; Luchetti S; Piaggio G; Parodi C; Li Pira G; Manca F; Carella AM
Exp Hematol; 2000 Jan; 28(1):104-11. PubMed ID: 10658682
[TBL] [Abstract][Full Text] [Related]
70. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
Nieborowska-Skórska M; Nakashima M; Ratajczak M; Steplewski Z; Calabretta B; Skórski T
Folia Histochem Cytobiol; 1994; 32(1):35-40. PubMed ID: 8026602
[TBL] [Abstract][Full Text] [Related]
71. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
Calabretta B; Sims RB; Valtieri M; Caracciolo D; Szczylik C; Venturelli D; Ratajczak M; Beran M; Gewirtz AM
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2351-5. PubMed ID: 2006173
[TBL] [Abstract][Full Text] [Related]
72. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Szczylik C; Skorski T; Nicolaides NC; Manzella L; Malaguarnera L; Venturelli D; Gewirtz AM; Calabretta B
Science; 1991 Aug; 253(5019):562-5. PubMed ID: 1857987
[TBL] [Abstract][Full Text] [Related]
73. Antisense oligonucleotide therapeutics for human leukemia.
Gewirtz AM
Curr Opin Hematol; 1998 Jan; 5(1):59-71. PubMed ID: 9515205
[TBL] [Abstract][Full Text] [Related]
74. Antisense of oligonucleotides and the inhibition of oncogene expression.
Prins J; de Vries EG; Mulder NH
Clin Oncol (R Coll Radiol); 1993; 5(4):245-52. PubMed ID: 8398922
[TBL] [Abstract][Full Text] [Related]
75. Chronic myeloid leukaemia--the XXI century.
Goldman JM
Leuk Lymphoma; 1993; 11 Suppl 1():7-9. PubMed ID: 8251921
[TBL] [Abstract][Full Text] [Related]
76. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Rapozzi V; Cogoi S; Xodo LE
Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
[TBL] [Abstract][Full Text] [Related]
77. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
Dickinson AM; Middleton SL; Latham J; Dunn J; Thomas L; Proctor SJ
Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
[TBL] [Abstract][Full Text] [Related]
78. Chronic myelogenous leukemia: molecular and cellular aspects.
Pasternak G; Hochhaus A; Schultheis B; Hehlmann R
J Cancer Res Clin Oncol; 1998; 124(12):643-60. PubMed ID: 9879825
[TBL] [Abstract][Full Text] [Related]
79. How do antisense oligodeoxynucleotides inhibit the growth of chronic myelogenous leukemia cells?
Bergan R; Neckers L
Blood; 1996 May; 87(9):4019-20. PubMed ID: 8611740
[No Abstract] [Full Text] [Related]
80. [Chronic myeloid leukemia. New prospects for marrow autotransplantation].
Carella AM; Carlier P; Nati S; Congiu A; Pierluigi D; Raffo MR
Haematologica; 1991 Jun; 76 Suppl 3():337-51. PubMed ID: 1684348
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
